Clinical Research Directory
Browse clinical research sites, groups, and studies.
Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity
Sponsor: Icahn School of Medicine at Mount Sinai
Summary
This project aims to determine the benefits of the dual SGLT1/2 inhibition as prophylactic treatment to prevent anthracycline-related cardiotoxicity.
Official title: SPARTACUS Trial (Sotagliflozin as Prevention of Antracycline-Related Toxicity in Adipose, Cardiac and mUskuloSkeletal Tissues)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-07
Completion Date
2029-10
Last Updated
2026-05-07
Healthy Volunteers
No
Interventions
Sotagliflozin
Sotagliflozin 400mg starting prior to the first scheduled anthracycline infusion
Placebo
Placebo starting prior to the first scheduled anthracycline infusion
Locations (1)
Icahn School of Medicine at Mount Sinai
New York, New York, United States